229,753 Shares of Medtronic PLC $MDT Bought by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new position in shares of Medtronic PLC (NYSE:MDT) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 229,753 shares of the medical technology company’s stock, valued at approximately $20,009,000.

Several other institutional investors have also added to or reduced their stakes in MDT. Kennebec Savings Bank boosted its position in shares of Medtronic by 1.2% in the third quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company’s stock valued at $794,000 after acquiring an additional 110 shares during the period. Petredis Investment Advisors LLC increased its position in Medtronic by 0.4% during the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock worth $2,275,000 after acquiring an additional 114 shares during the period. Aviance Capital Partners LLC increased its position in Medtronic by 2.1% during the third quarter. Aviance Capital Partners LLC now owns 5,469 shares of the medical technology company’s stock worth $472,000 after acquiring an additional 114 shares during the period. Arlington Trust Co LLC increased its position in Medtronic by 11.6% during the second quarter. Arlington Trust Co LLC now owns 1,157 shares of the medical technology company’s stock worth $91,000 after acquiring an additional 120 shares during the period. Finally, Bank & Trust Co raised its stake in Medtronic by 2.8% in the 2nd quarter. Bank & Trust Co now owns 4,373 shares of the medical technology company’s stock worth $342,000 after purchasing an additional 121 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic reported that the SPYRAL AFFIRM real-world study found statistically significant, clinically meaningful blood-pressure reductions six months after treatment with its Symplicity Spyral system. Reductions were seen in office, home, and 24-hour ambulatory readings, without an increase in antihypertensive medications. The findings could strengthen the case for the procedure and support future adoption, though the announcement does not quantify potential sales impact. Article
• Neutral Sentiment: Medtronic and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson’s and caregivers understand deep brain stimulation (DBS). It may raise awareness of an established treatment, but no new product, clinical result, or revenue outlook was announced. Article
• Neutral Sentiment: The company said it will release fiscal Q2 2027 results on November 24. This is a scheduling announcement, with no new financial guidance or operating results. Article
• Negative Sentiment: A report said ETFs were net sellers of MDT, with $110.6 million in outflows on Friday. This is a short-term flow signal and may not indicate a lasting change in investor views. Article
• Negative Sentiment: An analyst roundup cited a consensus price target of $102.88, below the $105.02 reference price in the supplied market data, suggesting limited upside at that level. Article

Medtronic Stock Performance

NYSE MDT opened at $105.02 on Thursday. The firm’s 50 day simple moving average is $92.21 and its 200 day simple moving average is $88.39. The firm has a market capitalization of $134.34 billion, a price-to-earnings ratio of 25.87, a P/E/G ratio of 2.31 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the previous year, the business earned $1.26 earnings per share. The company’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 2.7%. Medtronic’s dividend payout ratio is 70.94%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MDT. TD Cowen restated a “buy” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, September 30th. Wells Fargo & Company lifted their price target on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. Bank of America lifted their price target on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Wednesday, October 14th. Finally, Barclays raised Medtronic to a “hold” rating in a research report on Wednesday, October 7th. Eighteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $102.88.

Insider Transactions at Medtronic

In other news, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares of the company’s stock, valued at approximately $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is currently owned by insiders.

Medtronic Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.